Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memmat: Metronomic and targeted anti-angiogenesis therapy for recurrent/progressive medulloblastoma
2011-001512-65Phase 2Completed
- Sponsor
- Masaryk University
- Start
- Apr 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide, celecoxib, fenofibrate, etoposide and cyclophosphamide in medulloblastoma, sponsored by Masaryk University. Primary endpoint: Objective treatment response. Started Apr 2012; status: completed.
02
Drugs
thalidomidecelecoxibfenofibrateetoposidecyclophosphamide
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on 2011-001512-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001512-65.